Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
Financial framing remained anchored on the same runway and 2026 cash operating expense guidance, while Q1 2026 highlighted a "30% year-over-year reduction" in cash operating expenses and quarter-end ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
Penn Engineers have developed a new way to use AI to solve inverse partial differential equations (PDEs), a particularly ...
Penn researchers have developed a smarter AI method for solving notoriously difficult inverse equations, which help ...
According to Rogers, the computer science faculty use Gradescope’s Measure Of Software Similarity (MOSS) tool to identify ...
A ripple tells you something happened, but not exactly what. That is the core problem behind a hard class of equations that ...
Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology ...
Researchers at the University of Pennsylvania have introduced a new way to use artificial intelligence to tackle one of the most difficult challenges in mathematics: inverse partial differential ...
ByteDance Is Building Drug Discovery AI and It Is Presenting at the World’s Best Science Conferences
ByteDance's drug discovery unit Anew Labs presented AI-designed autoimmune therapies at Immunology2026 in Boston, attended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results